CohBar Inc (CWBR)
0.49
-0.02
(-4.02%)
USD |
OTCM |
Nov 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.424M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -41.25% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.83% |
Profile
| CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States. |
| URL | https://www.cohbar.com |
| Investor Relations URL | https://www.cohbar.com/investors |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 19, 2024 (est.) |
| Last Earnings Release | Nov. 15, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States. |
| URL | https://www.cohbar.com |
| Investor Relations URL | https://www.cohbar.com/investors |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 19, 2024 (est.) |
| Last Earnings Release | Nov. 15, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |